450
Participants
Start Date
October 14, 2024
Primary Completion Date
September 19, 2025
Study Completion Date
November 30, 2025
A haemostatic mineral powder product.
The intervention is the addition of an approved and commercially available haemostatic powder product which is indicated for the temporary external control of bleeding. Recommended application is at central venous catheter insertion, prior to the site being covered with a transparent dressing. Comprising a hydrophilic polymer and potassium ferrate, once in contact with protein-rich body fluids, the mechanism of action of the powder is to dehydrate and to absorb exudate. This simultaneously forms a low pH seal barrier which is hostile to microbial penetration while also purporting to help maintain clean and dry environment beneath transparent site dressings.
Liverpool Heart and Chest Hospital NHS FoundationTrust, Liverpool
Biolife LLC
UNKNOWN
Liverpool Heart and Chest Hospital NHS Foundation Trust
OTHER